InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+11.8%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by RICHMAN ERIC I, Chairman & CEO. Director active across 2 companies, notably Gain Therapeutics, Inc.. Cumulatively, 8 reports have been published. Breakdown: 5 buys · 0 sell. Total volume traded: €57k. History available since 16 August 2021. The latest transaction was disclosed on 1 July 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations8 total
5,000 shares@ US$1.234.8% of flowCommon StockSEC:0001493152-24-025831:0
Ideal exit: 28 Mar 2025 (T+270)
54,900 sharesCommon StockSEC:0001209191-23-050380:0
2,482 shares@ US$2.580.0080% mcap5.2% of flowCommon stockSEC:0001415889-22-005798:0
Ideal exit: 19 Feb 2023 (T+270)
4,000 shares@ US$2.710.014% mcap8.9% of flowCommon stockSEC:0001415889-22-005501:0
Ideal exit: 13 Feb 2023 (T+270)
4,922 shares@ US$7.8660.044% mcap28.6% of flowCommon StockSEC:0001209191-22-025180:0
Ideal exit: 13 May 2022 (T+270)
1,580 shares@ US$1.58100.0% of flowCommon stockSEC:0001104659-22-031172:0
Ideal exit: 26 Nov 2022 (T+270)
4,922 shares@ US$7.86627.3% of flowCommon StockSEC:0001104659-21-107121
4,922 shares@ US$7.8660.044% mcap28.6% of flowCommon StockSEC:0001104659-21-107121:0
8 of 8 declarations
About RICHMAN ERIC I
Eric I. Richman is a Director and Chief Executive Officer of Gain Therapeutics, Inc. and NeuBase Therapeutics, Inc. In these roles, he oversees the operations of the companies and is responsible for the overall strategy. Eric leverages his expertise to lead these companies towards growth and innovation initiatives.
